SCYNEXIS, INC. - 10-K Filing Summary
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended December 31, 2024. SCYNEXIS, Inc. is a biotechnology company developing a novel class of antifungal agents called "fungerps" (triterpenoids). The company's lead asset is ibrexafungerp (BREXAFEMME), approved for vulvovaginal candidiasis (VVC) and recurrent VVC. In March 2023, the company entered a global license agreement with GlaxoSmithKline (GSK) for the development and commercialization of ibrexafungerp outside of Greater China and certain other regions. A second-generation compound, SCY-247, is in Phase 1 clinical development.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $3.7 million | $140.1 million |
| Net Loss | $(21.3) million | $67.0 million (Income) |
| Operating Expenses | $40.9 million | $67.5 million |
| Cash, Cash Equivalents, and Investments | $75.1 million | $98.0 million |
| Accumulated Deficit | $(376.5) million | $(355.2) million |
| Net Cash Used in Operating Activities | $(24.0) million | $60.2 million (Provided) |
Note: 2023 results included a $90.0 million upfront payment and $45.0 million in milestone revenue from the GSK agreement, as well as a $14.6 million inventory impairment charge related to the product recall.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 97.3% to $3.7 million in 2024 compared to $140.1 million in 2023. This is primarily due to the recognition of the $130.1 million GSK license revenue in 2023. In 2024, revenue consisted of $3.7 million in license agreement revenue (including a $10.0 million milestone for completed studies) and zero product revenue due to the ongoing recall.
- Profitability Shift: The company reported a net loss of $21.3 million in 2024, reversing the net income of $67.0 million in 2023. The 2023 income was driven by the GSK upfront payment and a $13.8 million gain on warrant liability fair value adjustment in 2024.
- Expense Reduction: Operating expenses decreased by 39.4% to $40.9 million. Research and Development (R&D) expenses fell 14.6% to $26.4 million, largely due to the clinical hold on the Phase 3 MARIO study. Selling, General, and Administrative (SG&A) expenses dropped 30.9% to $14.5 million, driven by lower professional fees and commercial costs.
- Liquidity: Cash and investments decreased by approximately $22.9 million year-over-year, reflecting ongoing operational burn despite the milestone receipt.
Guidance, Outlook, Risks, and Unusual Items
- Product Recall and Clinical Hold: The most significant unusual item is the voluntary recall of BREXAFEMME and a temporary clinical hold on ibrexafungerp studies (including the Phase 3 MARIO study) initiated in 2023. This was due to potential cross-contamination with a beta-lactam compound at a manufacturing vendor. The company anticipates restarting the MARIO study in Q2 2025 pending FDA approval.
- Amended GSK Agreement: In December 2023, the GSK License Agreement was amended. Potential milestone payments were revised downward (e.g., regulatory milestones reduced from $70M to $49M; commercial milestones from $115M to $57.5M) to reflect the delay in commercialization.
- SCY-247 Progress: The company initiated a Phase 1 study for SCY-247 in Q4 2024. Data release is expected in Q3 2025.
- Litigation: A securities class action lawsuit and shareholder derivative complaints were filed in late 2023 and 2024, alleging failure to disclose manufacturing risks and internal control deficiencies. The company intends to defend these vigorously; cases are currently stayed.
- Liquidity Outlook: Management believes current capital resources ($75.1 million) are sufficient to fund operations for at least 12 months. However, the company expects to incur significant losses and will require additional capital to continue development.
Key Facts for Investor Verification
- Recall Resolution Timeline: Verify the status of the FDA clinical hold and the specific timeline for the restart of the Phase 3 MARIO study (currently projected for Q2 2025).
- Manufacturing Supply Chain: Confirm the details of the new manufacturing agreements with third-party vendors intended to resolve the beta-lactam cross-contamination risk.
- GSK Milestone Probability: Assess the likelihood of achieving the remaining development milestones (up to $37.35 million) under the amended GSK agreement, specifically the resumption of the MARIO study.
- Capital Requirements: Evaluate the company's burn rate and the potential need for equity dilution or debt financing given the $75.1 million cash position and ongoing R&D costs.
- Legal Exposure: Monitor the status of the securities class action and derivative lawsuits regarding the manufacturing disclosure issues.